{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:29:47Z","timestamp":1792085387504,"version":"4.4.0"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:sec id=\"ab-dbr260008-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>The incidence of cutaneous squamous cell carcinoma of the head and neck (cSCCHN) has increased, including among those with high-risk disease. Delays to access and initiation of care are associated with disease progression and worse outcomes. Capecitabine has previously been shown to be effective antitumor activity with low toxic effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-dbr260008-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy and tolerability of neoadjuvant capecitabine (NC) in advanced cSCCHN by evaluating the clinical and pathologic stage migration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-dbr260008-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This prospective case series was conducted from January 2024 to September 2025 at 2 academic centers in Montreal, Canada, and included consecutive patients with advanced cSCCHN who were awaiting surgery. The data were analyzed in November 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-dbr260008-7\">\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>Two cycles of NC (1000 mg, twice daily, on days 1-14, followed by a 1-week rest period) were administered according to the Capecitabine Prior to Tumor Resection in ENT Oncology (CAPTURE) protocol, with surgical resection performed within 1 to 2 weeks after treatment completion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-dbr260008-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Clinical tumor response and clinical to pathologic stage migration, defined as the comparison of initial clinical stage with the postsurgical pathologic stage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-dbr260008-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean (SD) age of the cohort of 15 patients was 77 (8.1) years; 6 patients (40%) were female, and 9 patients (60%) were male. Clinical tumor regression was observed in 10 of 15 patients (67%). Among those who underwent resection, 5 (42%) achieved a complete pathologic response. Two patients avoided surgery due to complete treatment response and opted to receive radiotherapy. Nonresponse occurred for 5 patients, including 1 patient who experienced progression to metastatic disease. No grade 3 or higher capecitabine-related toxic effects were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-dbr260008-10\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case series found that NC demonstrated significant tumor regression and pathologic response without severe treatment-related toxic effects. NC may be an effective treatment option for providing disease control and tumor downstaging in patients with advanced cSCCHN.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamadermatol.2026.1331","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:30:26Z","timestamp":1779895826000},"page":"813","source":"Crossref","is-referenced-by-count":1,"title":["Neoadjuvant Capecitabine in Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck"],"prefix":"10.1001","volume":"162","author":[{"given":"Savanah","family":"Haidar","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Mlynarek","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Lefrancois","sequence":"additional","affiliation":[{"name":"Division of Dermatology, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Roshdy","sequence":"additional","affiliation":[{"name":"Division of Dermatology, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Khanna","sequence":"additional","affiliation":[{"name":"Division of Dermatology, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"Fortier-Riberdy","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Richardson","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Florianova","sequence":"additional","affiliation":[{"name":"Department of Pathology, McGill University, Jewish General Hospital, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pusztaszeri","sequence":"additional","affiliation":[{"name":"Department of Pathology, McGill University, Jewish General Hospital, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derin","family":"Caglar","sequence":"additional","affiliation":[{"name":"Department of Pathology, McGill University Health Centre, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader","family":"Sadeghi","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, McGill University, Montreal, Quebec, Canada"},{"name":"Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hier","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil","family":"Sultanem","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, Department of Oncology, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Tsien","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, Department of Oncology, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Bouganim","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khashayar","family":"Esfahani","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco A.","family":"Mascarella","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, McGill University, Montreal, Quebec, Canada"},{"name":"Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada"},{"name":"Centre of Clinical Epidemiology, Lady Davis Institute of the Jewish General Hospital, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"dbr260008r1","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.11S2a166S","article-title":"Risk factors and diagnosis of advanced cutaneous squamous cell carcinoma.","volume":"11","author":"Brancaccio","year":"2021","journal-title":"Dermatol Pract Concept"},{"issue":"7","key":"dbr260008r2","doi-asserted-by":"publisher","first-page":"6634","DOI":"10.3390\/curroncol30070487","article-title":"Aggressive cutaneous squamous cell carcinoma of the head and neck: a review.","volume":"30","author":"Desai","year":"2023","journal-title":"Curr Oncol"},{"issue":"1","key":"dbr260008r3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s40463-021-00529-7","article-title":"Prognostic factors of head and neck cutaneous squamous cell carcinoma: a systematic review.","volume":"50","author":"Lubov","year":"2021","journal-title":"J Otolaryngol Head Neck Surg"},{"issue":"8","key":"dbr260008r4","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.3390\/cancers16081469","article-title":"Delay in cutaneous squamous cell carcinoma diagnosis due to interrupted services is associated with worse prognoses and modified surgical approaches.","volume":"16","author":"Taccioli","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"14","key":"dbr260008r5","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.3390\/healthcare11141994","article-title":"COVID-19 and cutaneous squamous cell carcinoma\u2014impact of the pandemic on unequal access to healthcare.","volume":"11","author":"Jovic","year":"2023","journal-title":"Healthcare (Basel)"},{"issue":"19","key":"dbr260008r6","doi-asserted-by":"publisher","first-page":"5582","DOI":"10.3390\/jcm11195582","article-title":"Capecitabine\u2014a \u201cpermanent mission\u201d in head and neck cancers \u201cwar council\u201d?","volume":"11","author":"Mire?tean","year":"2022","journal-title":"J Clin Med"},{"issue":"17","key":"dbr260008r8","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJMoa2209813","article-title":"Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma.","volume":"387","author":"Gross","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"dbr260008r9","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1056\/NEJMoa2502449","article-title":"Adjuvant cemiplimab or placebo in high-risk cutaneous squamous-cell carcinoma.","volume":"393","author":"Rischin","year":"2025","journal-title":"N Engl J Med"},{"key":"dbr260008r10","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.2147\/CCID.S381471","article-title":"Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma: appropriate patient selection and perspectives.","volume":"16","author":"Mager","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"10","key":"dbr260008r11","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1097\/CAD.0b013e328358d226","article-title":"Efficacy and safety of capecitabine in heavily pretreated recurrent\/metastatic head and neck squamous cell carcinoma.","volume":"23","author":"P\u00e9ron","year":"2012","journal-title":"Anticancer Drugs"},{"issue":"6","key":"dbr260008r12","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1002\/ohn.1003","article-title":"Neoadjuvant capecitabine in operable HPV-negative head and neck cancer: fortuitous findings in a resource constrained setting.","volume":"171","author":"Mascarella","year":"2024","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"8","key":"dbr260008r13","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.3390\/molecules13081551","article-title":"5-Fluorouracil: mechanisms of resistance and reversal strategies.","volume":"13","author":"Zhang","year":"2008","journal-title":"Molecules"},{"issue":"6","key":"dbr260008r14","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/j.jdcr.2015.09.009","article-title":"Capecitabine for squamous cell carcinoma reduction in solid organ transplant recipients.","volume":"1","author":"Breithaupt","year":"2015","journal-title":"JAAD Case Rep"},{"issue":"9","key":"dbr260008r15","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1200\/JCO.23.01498","article-title":"Cemiplimab for kidney transplant recipients with advanced cutaneous squamous cell carcinoma.","volume":"42","author":"Hanna","year":"2024","journal-title":"J Clin Oncol"},{"key":"dbr260008r7","unstructured":"National Cancer Institute. Testing the addition of an immunotherapy drug, cemiplimab (REGN2810), plus surgery to the usual surgery alone for treating advanced skin cancer. Accessed November 29, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06568172"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2849570\/jamadermatology_haidar_2026_br_260008_1786734810.07586.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T15:00:26Z","timestamp":1787151626000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2849570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2026.1331","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}